0000000000324946

AUTHOR

Maria Jose Sayas

showing 4 related works from this author

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

2021

We have analyzed treatment patterns and outcomes of relapsed/refractory(R/R) FLT3mut AML adult patients registered in our institutional data base between 1998 and 2018. Overall, 147 patients were evaluable: 34 from 1998 to 2009, 113 from 2010 to 2018. Salvage treatments were intensive chemotherapy ( n = 25, 74%), and supportive care ( n = 9, 26%) in the 1998-2009 period, and intensive chemotherapy ( n = 63, 56%), hypomethylating agent ( n = 7, 6%), low-dose cytarabine-based ( n = 8, 7%), clinical trial ( n = 16, 14%) and supportive care ( n = 19, 17%) in the 2010-2018 period. Complete remission (CR) or with incomplete recovery (CRi) rate was 44%, 49% among patients treated intensively (vs 3…

OncologyAdultCancer Researchmedicine.medical_specialtyreal-world*real-world03 medical and health sciences0302 clinical medicineRefractoryInternal medicineAntineoplastic Combined Chemotherapy Protocolsmedicine*FLT3mut AMLHumansPatterns of carerelapseSalvage TherapyAdult patientsFLT3mut AMLbusiness.industryFLT3mut AML real-world relapse/refractoryRemission InductionCytarabineMyeloid leukemiaHematology*relapse/refractoryrefractoryLeukemia Myeloid AcuteTreatment OutcomeOncologyfms-Like Tyrosine Kinase 3030220 oncology & carcinogenesisRelapsed refractorybusiness030215 immunologyLeukemialymphoma
researchProduct

Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemothe…

2010

Purpose We analyzed the incidence, risk factors, and outcome of therapy-related myeloid neoplasms (t-MNs) in patients with acute promyelocytic leukemia (APL) in first complete remission (CR). Patients and Methods From 1996 to 2008, 1,025 patients with APL were enrolled onto three sequential trials (LPA96, LPA99, and LPA2005) of the Programa Español para el Tratamiento de Enfermedades Hematológicas and received induction and consolidation therapy with all-trans-retinoic acid (ATRA) and anthracycline-based chemotherapy. Results Seventeen of 918 patients who achieved CR developed t-MN (10 with < 20% and seven with ≥ 20% of bone marrow blasts) after a median of 43 months from CR. Partial and…

Acute promyelocytic leukemiaAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAnthracyclinemedicine.medical_treatmentTretinoinGastroenterologyLeukemia Promyelocytic AcuteTretinoinRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCumulative incidenceAnthracyclinesProspective StudiesAgedChemotherapybusiness.industryIncidenceNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisSurgeryLeukemiamedicine.anatomical_structureTreatment OutcomeOncologyFemaleBone marrowbusinessBone Marrow Neoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Pat…

2019

BACKGROUND: Older patients with acute myeloid leukaemia (AML) who are unsuitable for standard induction therapy have limited treatment options. While DNMT3A, TET2, IDH1/2 and TP53 mutations have been previously associated to better response to hypomethylating agents, there are no molecular biomarkers for low-dose cytarabine (LDAC)-based regimens. AIMS: To predict outcome in AML older patients at diagnosis based on mutation status in the context of FLUGAZA trial. FLUGAZA trial was focus on >65 years AML de novo patients comparing azacytidine vs. fludarabine and LDAC (FLUGA Scheme). METHODS: We analyzed bone marrow (BM) samples at diagnosis from 209 out of 285 AML patients treated accordin…

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyAzacitidineLow dose cytarabineMyeloid leukemiaCell BiologyHematologymedicine.diseaseBiochemistryFludarabineLeukemiamedicine.anatomical_structureInternal medicinemedicineCytarabineBone marrowbusinessNeoadjuvant therapymedicine.drug
researchProduct

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience

2020

Introduction The prognosis of patients with recurrent or refractory acute myeloid leukemia (AML-RR) is very poor, especially if they are not candidates for allogeneic transplantation (allo-SCT) after a second complete response (CR). Venetoclax, a potent and selective inhibitor of the antiapoptotic protein BCL-2, was approved by the FDA in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) in patients with newly diagnosed AML of age ≥ 75 years, or who have comorbidities that preclude the use of intensive chemotherapy. However, the evidence in AML-RR patients is still scarce. For this reason, the objective of our study is to retrospectively analyze the efficacy of th…

medicine.medical_specialtyVenetoclaxbusiness.industryImmunologyDecitabineCell BiologyHematologymedicine.diseaseBiochemistryDiscontinuationRegimenchemistry.chemical_compoundLeukemiachemistryRefractoryInternal medicineCohortmedicineCytarabinebusinessmedicine.drugBlood
researchProduct